R
Reingard Stuhlmann
Publications - 19
Citations - 1511
Reingard Stuhlmann is an academic researcher. The author has contributed to research in topics: Transplantation & Cytarabine. The author has an hindex of 14, co-authored 19 publications receiving 1311 citations.
Papers
More filters
Journal ArticleDOI
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Nicola Gökbuget,Daniel Stanze,Joachim Beck,Helmut Diedrich,Heinz-August Horst,Andreas Hüttmann,Guido Kobbe,Karl-Anton Kreuzer,Lothar Leimer,Albrecht Reichle,Markus Schaich,Stefan Schwartz,Hubert Serve,Michael Starck,Matthias Stelljes,Reingard Stuhlmann,Andreas Viardot,Knut Wendelin,Mathias Freund,Dieter Hoelzer +19 more
TL;DR: Overall survival appeared superior compared with previously published studies, likely because of the high rate of SCT in the present study (75%).
Journal ArticleDOI
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve,Utz Krug,Ruth Wagner,M. Cristina Sauerland,Achim Heinecke,Uta Brunnberg,Markus Schaich,Oliver G. Ottmann,Justus Duyster,Hannes Wandt,Thomas Fischer,Aristoteles Giagounidis,Andreas Neubauer,Albrecht Reichle,Walter E. Aulitzky,Richard Noppeney,Igor Wolfgang Blau,Volker Kunzmann,Reingard Stuhlmann,Alwin Krämer,Karl-Anton Kreuzer,Christian Brandts,Björn Steffen,Christian Thiede,Carsten Müller-Tidow,Gerhard Ehninger,Wolfgang E. Berdel +26 more
TL;DR: Combination of standard induction and consolidation therapy with sorafenib in the schedule investigated in the trial is not beneficial for elderly patients with AML.
Journal ArticleDOI
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Röllig,Martin Bornhäuser,Christian Thiede,Franziska Taube,Michael S. Kramer,Brigitte Mohr,Walter E. Aulitzky,Heinrich Bodenstein,Hans-Joachim Tischler,Reingard Stuhlmann,Ulrich Schuler,Friedrich Stölzel,Malte von Bonin,Hannes Wandt,Kerstin Schäfer-Eckart,Markus Schaich,Gerhard Ehninger +16 more
TL;DR: In younger patients with AML, the ELN classification seems to be the best available framework for prognostic estimations to date, and caution is advised concerning its use for prospective treatment allocation before it has been prospectively validated.
Journal ArticleDOI
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Röllig,Christian Thiede,Martin Gramatzki,Walter E. Aulitzky,Heinrich Bodenstein,Martin Bornhäuser,Uwe Platzbecker,Reingard Stuhlmann,Ulrich Schuler,Silke Soucek,Michael S. Kramer,Brigitte Mohr,Uta Oelschlaegel,Friedrich Stölzel,Malte von Bonin,Martin Wermke,Hannes Wandt,Gerhard Ehninger,Markus Schaich +18 more
TL;DR: An analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years revealed that karyotype, age, NPM1 mutation status, white blood cell count, lactate dehydrogenase, and CD34 expression were of independent prognostic significance for OS.
Journal ArticleDOI
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study
Markus Schaich,Christoph Röllig,Silke Soucek,Michael Kramer,Christian Thiede,Brigitte Mohr,Uta Oelschlaegel,Norbert Schmitz,Reingard Stuhlmann,Hannes Wandt,Kerstin Schäfer-Eckart,Walter E. Aulitzky,Martin Kaufmann,Heinrich Bodenstein,Joachim Tischler,Anthony D. Ho,Alwin Krämer,Martin Bornhäuser,Johannes Schetelig,Gerhard Ehninger +19 more
TL;DR: In young adults with AML receiving intermediate-dose cytarabine induction, intensification of the cyTarabine dose beyond 12 g/m² within first consolidation did not improve treatment outcome.